Classifying Hypoxia in Breast Cancer Xenografts Using a Single-Cell Mass Spectrometry Imaging Model

Britt S. R. Claes, Rianne Biemans, Natasja Lieuwes, Lynn Theunissen, Kristine Glunde, Ludwig Dubois, Ron M. A. Heeren*, Eva Cuypers

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Hypoxia is a common feature in solid tumors that arises when there is insufficient oxygen available. This lack of oxygen causes molecular adaptations required for the tumor cells to survive. Additionally, oxygen-deprived cancer cells tend to become less responsive to conventional cancer therapies. Hence, hypoxia plays an important role in contributing to tumor aggressiveness and therapy resistance. Hypoxia-related markers are gaining interest as prognostic and predictive markers for tumor response and treatment strategies. However, the detection of hypoxia in the tumor microenvironment without employing any labeling strategies poses significant challenges. Here, we present a classification model based on lipidomic single-cell mass spectrometry imaging data to classify hypoxia in breast cancer xenografts. Our approach is based on a classification model built from the lipid profiles of single breast cancer cells cultured under various oxygen conditions. Lipidomic alterations caused by differences in available oxygen concentrations were subsequently used to classify and spatially determine hypoxic regions in breast cancer xenografts without the need for any labeling. This approach, using cells as hypoxia markers, contributes to a better understanding of tumor biology and provides a foundation for improving diagnostic and therapeutic strategies for cancer treatments.
Original languageEnglish
Number of pages4
JournalAnalysis & Sensing
DOIs
Publication statusE-pub ahead of print - 1 Jan 2025

Keywords

  • Hypoxia
  • Lipids
  • Cancer
  • Classification
  • Mass spectrometry imaging
  • PIMONIDAZOLE

Fingerprint

Dive into the research topics of 'Classifying Hypoxia in Breast Cancer Xenografts Using a Single-Cell Mass Spectrometry Imaging Model'. Together they form a unique fingerprint.

Cite this